Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer

Keyphrases

• Adjuvant Trastuzumab 10%
• African Countries 30%
• Breast Cancer 10%
• Cause of Death 10%
• Clinical Trial Data 10%
• Common Cancers 10%
• Congo 10%
• Cost-effectiveness 100%
• Discount Rate 10%
• Extracellular Domain 10%
• GDP per Capita 10%
• Hazard Ratio 10%
• HER2 mutation 10%
• HER2-positive Breast Cancer 100%
• Incremental Cost 10%
• Incremental Cost-effectiveness Ratio 10%
• Less Developed Regions 10%
• Markov Model 10%
• Monoclonal Antibody 10%
• Nigeria 40%
• Parameter Uncertainty 10%
• Parameter Values 10%
• Probabilistic Sensitivity Analysis 10%
• Societal Perspective 10%
• South Africa 30%
• Sub-Saharan Africa 100%
• Trastuzumab 100%
• Treatment Costs 10%
• Value-based Pricing 10%
• Willingness to Pay 10%
• World Health Organization Recommendations 10%

Immunology and Microbiology

• Head 9%
• Lifespan 9%
• Monoclonal Antibody 9%
• Quality Adjusted Life Year 36%
• Trastuzumab 100%

Agricultural and Biological Sciences

• African 27%
• Head 9%
• Monoclonal Antibody 9%
• Trastuzumab 100%
• World Health Organization 9%